Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice

Antiviral Research

Volumn 86, Issue 3, 2010, Pages 276-285

  Rowe, Jenny ^a   Greenblatt, Rebecca J ^a   Liu, Dongmei ^a   Moffat, Jennifer F ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Antiviral; Cyclin dependent kinase; Kinase inhibitor; Roscovitine; SCID Hu mouse; Skin organ culture; Varicella zoster virus

Indexed keywords

ACICLOVIR; ALOISINE A; APHIDICOLIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; MIMOSINE; PHOSPHONOACETIC ACID; PURVALANOL A; ROSCOVITINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BIOLUMINESCENCE; CELL CYCLE ARREST; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; DRUG TREATMENT FAILURE; ENZYME INHIBITION; EX VIVO STUDY; GENE DOSAGE; HERPES ZOSTER; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA TRANSCRIPTION; SCID MOUSE; VARICELLA ZOSTER VIRUS; VIRUS CELL INTERACTION; VIRUS CULTURE; VIRUS PLAQUE; VIRUS REPLICATION; XENOGRAFT;

ANIMALS; ANTIVIRAL AGENTS; CELL SURVIVAL; CELLS, CULTURED; CHICKENPOX; CYCLIN-DEPENDENT KINASES; DNA, VIRAL; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FIBROBLASTS; HERPESVIRUS 3, HUMAN; HUMANS; LUMINESCENT MEASUREMENTS; MICE; MICE, SCID; NEUTRAL RED; ORGAN CULTURE TECHNIQUES; PLAQUE ASSAY; SKIN; STAINING AND LABELING; VIRUS REPLICATION;

HERPESVIRIDAE; HUMAN HERPESVIRUS 3; MUS; PAA;

EID: 77952673388     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.03.007     Document Type: Article

References (64)

1. Alconada A., Bauer U., Hoflack B. A tyrosine-based motif and a casein kinase II phosphorylation site regulate the intracellular trafficking of the varicella-zoster virus glycoprotein I, a protein localized in the trans-Golgi network. Embo J. 1996, 15:6096-6110.
2. Babich H., Sedletcaia A., Kenigsberg B. In vitro cytotoxicity of protocatechuic acid to cultured human cells from oral tissue: involvement in oxidative stress. Pharmacol. Toxicol. 2002, 91:245-253.
3. Bresnahan W.A., Boldogh I., Chi P., Thompson E.A., Albrecht T. Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication. Virology 1997, 231:239-247.
4. Carpenter J.E., Henderson E.P., Grose C. Enumeration of an extremely high particle-to-PFU ratio for Varicella-zoster virus. J. Virol. 2009, 83:6917-6921.
5. Cohen J.I., Sato H., Srinivas S., Lekstrom K. Varicella-zoster virus (VZV) ORF65 virion protein is dispensable for replication in cell culture and is phosphorylated by casein kinase II, but not by the VZV protein kinases. Virology 2001, 280:62-71.
6. Cohen J.I., Straus S.E. Varicella-zoster virus and its replication. Fields Virology 2001, vol.2:2707-2730. Lippincott-Raven, Philadelphia. fourth ed.
7. Corbel C., Haddoub R., Guiffant D., Lozach O., Gueyrard D., Lemoine J., Ratin M., Meijer L., Bach S., Goekjian P. Identification of potential cellular targets of aloisine A by affinity chromatography. Bioorg. Med. Chem. 2009, 17:5572-5582.
8. De Clercq E. Antiviral drugs in current clinical use. J. Clin. Virol. 2004, 30:115-133.
9. Diwan P., Lacasse J.J., Schang L.M. Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors. J. Virol. 2004, 78:9352-9365.
10. Dothager R.S., Flentie K., Moss B., Pan M.H., Kesarwala A., Piwnica-Worms D. Advances in bioluminescence imaging of live animal models. Curr. Opin. Biotechnol. 2009, 20:45-53.
11. Goga A., Yang D., Tward A.D., Morgan D.O., Bishop J.M. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat. Med. 2007, 13:820-827.
12. Habran L., Bontems S., Di Valentin E., Sadzot-Delvaux C., Piette J. Varicella-zoster virus IE63 protein phosphorylation by roscovitine-sensitive cyclin-dependent kinases modulates its cellular localization and activity. J. Biol. Chem. 2005, 280:29135-29143.
13. Hay J., Brown S.M., Jamieson A.T., Rixon F.J., Moss H., Dargan D.A., Subak-Sharpe J.H. The effect of phosphonoacetic acid on herpes viruses. J. Antimicrob. Chemother. 1977, 3(Suppl A):63-70.
14. Holcomb K., Weinberg J.M. A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia. J. Drugs Dermatol. 2006, 5:863-866.
15. Huang E.S., Huang C.H., Huong S.M., Selgrade M. Preferential inhibition of herpes-group viruses by phosphonoacetic acid: effect on virus DNA synthesis and virus-induced DNA polymerase activity. Yale J. Biol. Med. 1976, 49:93-99.
16. Johnson R.W., Wasner G., Saddier P., Baron R. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging 2008, 25:991-1006.
17. Kabir J., Lobo M., Zachary I. Staurosporine induces endothelial cell apoptosis via focal adhesion kinase dephosphorylation and focal adhesion disassembly independent of focal adhesion kinase proteolysis. Biochem. J. 2002, 367:145-155.
18. Knockaert M., Gray N., Damiens E., Chang Y.T., Grellier P., Grant K., Fergusson D., Mottram J., Soete M., Dubremetz J.F., Le Roch K., Doerig C., Schultz P., Meijer L. Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. Chem. Biol. 2000, 7:411-422.
19. Knockaert M., Lenormand P., Gray N., Schultz P., Pouysségur J., Meijer L. p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol. Oncogene 2002, 21:6413-6424.
20. Kudoh A., Daikoku T., Sugaya Y., Isomura H., Fujita M., Kiyono T., Nishiyama Y., Tsurumi T. Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication. J. Virol. 2004, 78:104-115.
21. Leisenfelder S.A., Moffat J.F. Varicella-zoster virus infection of human foreskin fibroblast cells results in atypical cyclin expression and cyclin-dependent kinase activity. J. Virol. 2006, 80:5577-5587.
22. Leisenfelder S.A., Kinchington P.R., Moffat J.F. Cyclin-dependent kinase 1/cyclin B1 phosphorylates varicella-zoster virus IE62 and is incorporated into virions. J. Virol. 2008, 82:12116-12125.
23. Luker G.D., Bardill J.P., Prior J.L., Pica C.M., Piwnica-Worms D., Leib D.A. Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice. J. Virol. 2002, 76:12149-12161.
24. Luker K.E., Luker G.D. Applications of bioluminescence imaging to antiviral research and therapy: multiple luciferase enzymes and quantitation. Antiviral Res. 2008, 78:179-187.
25. Meggio F., Shugar D., Pinna L.A. Ribofuranosyl-benzimidazole derivatives as inhibitors of casein kinase-2 and casein kinase-1. Eur. J. Biochem. 1990, 187:89-94.
26. Meggio F., Pinna L.A. One-thousand-and-one substrates of protein kinase CK2?. FASEB J. 2003, 17:349-368.
27. Meijer L., Raymond E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc. Chem. Res. 2003, 36:417-425.
28. Mettey Y., Gompel M., Thomas V., Garnier M., Leost M., Ceballos-Picot I., Noble M., Endicott J., Vierfond J.M., Meijer L. Aloisines, a new family of CDK/GSK-3 inhibitors, SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J. Med. Chem. 2003, 46:222-236.
29. Moffat J.F., Stein M.D., Kaneshima H., Arvin A.M. Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice. J. Virol. 1995, 69:5236-5242.
30. Moffat J.F., Zerboni L., Kinchington P.R., Grose C., Kaneshima H., Arvin A.M. Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J. Virol. 1998, 72:965-974.
31. Moffat J.F., Arvin A.M. Varicella-zoster virus infection of T cells and skin in the SCID-hu mouse model. Handbook of Animal Models of Infection 1999, 973-980. Academic Press, San Diego. O. Zak, M.A. Sande (Eds.).
32. Moffat J.F., McMichael M.A., Leisenfelder S.A., Taylor S.L. Viral and cellular kinases are potential antiviral targets and have a central role in varicella zoster virus pathogenesis. Biochim. Biophys. Acta 2004, 1697:225-231.
33. Mueller N.H., Graf L.L., Orlicky D., Gilden D., Cohrs R.J. Phosphorylation of the nuclear form of varicella-zoster virus immediate-early protein 63 by casein kinase II at serine 186. J. Virol. 2009, 83:12094-12100.
34. Nagaike K., Mori Y., Gomi Y., Yoshii H., Takahashi M., Wagner M., Koszinowski U., Yamanishi K. Cloning of the varicella-zoster virus genome as an infectious bacterial artificial chromosome in Escherichia coli. Vaccine 2004, 22:4069-4074.
35. Niizuma T., Zerboni L., Sommer M.H., Ito H., Hinchliffe S., Arvin A.M. Construction of Varicella-zoster virus recombinants from parent oka cosmids and demonstration that ORF65 protein is dispensable for infection of human skin and T cells in the SCID-hu mouse model. J. Virol. 2003, 77:6062-6065.
36. Oliver S.L., Zerboni L., Sommer M., Rajamani J., Arvin A.M. Development of recombinant varicella-zoster viruses expressing luciferase fusion proteins for live in vivo imaging in human skin and dorsal root ganglia xenografts. J. Virol. Methods 2008, 154:182-193.
37. Pedrali-Noy G., Spadari S. Mechanism of inhibition of herpes simplex virus and vaccinia virus DNA polymerases by aphidicolin, a highly specific inhibitor of DNA replication in eucaryotes. J. Virol. 1980, 36:457-464.
38. Perry C., Sastry R., Nasrallah I.M., Stover P.J. Mimosine attenuates serine hydroxymethyltransferase transcription by chelating zinc. Implications for inhibition of DNA replication. J. Biol. Chem. 2005, 280:396-400.
39. Pinna L.A., Meggio F. Protein kinase CK2 (" casein kinase-2" ) and its implication in cell division and proliferation. Prog. Cell Cycle Res. 1997, 3:77-97.
40. Prather R.S., Boquest A.C., Day B.N. Cell cycle analysis of cultured porcine mammary cells. Cloning 1999, 1:17-24.
41. Raynaud F.I., Fischer P.M., Nutley B.P., Goddard P.M., Lane D.P., Workman P. Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. Mol. Cancer Ther. 2004, 3:353-362.
42. Reardon J.E., Spector T. Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J. Biol. Chem. 1989, 264:7405-7411.
43. Renò F., Tontini A., Burattini S., Papa S., Falcieri E., Tarzia G. Mimosine induces apoptosis in the HL60 human tumor cell line. Apoptosis 1999, 4:469-477.
44. Repetto G., del Peso A., Zurita J.L. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat. Protoc. 2008, 3:1125-1131.
45. Sampathkumar P., Drage L.A., Martin D.P. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin. Proc. 2009, 84:274-280.
46. Sanchez V., McElroy A.K., Yen J., Tamrakar S., Clark C.L., Schwartz R.A., Spector D.H. Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production. J. Virol. 2004, 78:11219-11232.
47. Schang L.M., Rosenberg A., Schaffer P.A. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins. J. Virol. 2000, 74:2107-2120.
48. Schang L.M., Coccaro E., Lacasse J.J. Cdk inhibitory nucleoside analogs prevent transcription from viral genomes. Nucleosides Nucleotides Nucleic Acids 2005, 24:829-837.
49. Schang L.M. First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy. Expert Rev. Anti Infect. Ther. 2006, 4:953-956.
50. Taylor S.L., Kinchington P.R., Brooks A., Moffat J.F. Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus. J. Virol. 2004, 78:2853-2862.
51. Taylor S.L., Moffat J.F. Replication of varicella-zoster virus in human skin organ culture. J. Virol. 2005, 79:11501-11506.
52. Tischer B.K., Kaufer B.B., Sommer M., Wussow F., Arvin A.M., Osterrieder N. A self-excisable infectious bacterial artificial chromosome clone of varicella-zoster virus allows analysis of the essential tegument protein encoded by ORF9. J. Virol. 2007, 81:13200-13208.
53. Vafai A., Berger M. Zoster in patients infected with HIV: a review. Am. J. Med. Sci. 2001, 321:372-380.
54. Vázquez M., LaRussa P.S., Gershon A.A., Niccolai L.M., Muehlenbein C.E., Steinberg S.P., Shapiro E.D. Effectiveness over time of varicella vaccine. JAMA 2004, 291:851-855.
55. Verri A., Maga G., Spadari S., Ponti W., Strosselli S., Bonizzi L., Rocchi M., Poli G., Focher F. Aphidicolin inhibits in vitro the activity of pseudorabies virus (PRV) DNA polymerase and in vivo the viral proliferation. In Vivo 1994, 8:1041-1046.
56. Villerbu N., Gaben A.M., Redeuilh G., Mester J. Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities. Int. J. Cancer 2002, 97:761-769.
57. Wang S., Fischer P.M. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol. Sci. 2008, 29:302-313.
58. Wang X., Rosol M., Ge S., Peterson D., McNamara G., Pollack H., Kohn D.B., Nelson M.D., Crooks G.M. Dynamic tracking of human hematopoietic stem cell engraftment using in vivo bioluminescence imaging. Blood 2003, 102:3478-3482.
59. Yao Z., Jackson W., Grose C. Identification of the phosphorylation sequence in the cytoplasmic tail of the varicella-zoster virus Fc receptor glycoprotein gpI. J. Virol. 1993, 67:4464-4473.
60. Ye M., Duus K.M., Peng J., Price D.H., Grose C. Varicella-zoster virus Fc receptor component gI is phosphorylated on its endodomain by a cyclin-dependent kinase. J. Virol. 1999, 73:1320-1330.
61. Yoshii H., Somboonthum P., Takahashi M., Yamanishi K., Mori Y. Cloning of full length genome of varicella-zoster virus vaccine strain into a bacterial artificial chromosome and reconstitution of infectious virus. Vaccine 2007, 25:5006-5012.
62. Zapata H.J., Nakatsugawa M., Moffat J.F. Varicella-zoster virus infection of human fibroblast cells activates the c-Jun N-terminal kinase pathway. J. Virol. 2007, 81:977-990.
63. Zeuzem S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat. Clin. Pract. Gastroenterol. Hepatol. 2008, 5:610-622.
64. Zhang Z., Rowe J., Wang W., Sommer M., Arvin A., Moffat J., Zhu H. Genetic analysis of varicella-zoster virus ORF0 to ORF4 by use of a novel luciferase bacterial artificial chromosome system. J. Virol. 2007, 81:9024-9033.